Prescription drug · NDA
Conjupri (levamlodipine) NDC 24075-0413
Levamlodipine maleate 5 mg/5mg · Tablet · Oral · CSPC Ouyi Pharmaceutical Co. Ltd
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 24075-0413-3 | 24075041303 | 5 mg in 1 BOTTLE (24075-0413-3)Marketed from Oct 8, 2021 | |
| 24075-0413-5 | 24075041305 | 5 mg in 1 BOTTLE (24075-0413-5)Marketed from Oct 8, 2021 | |
| 24075-0413-9 | 24075041309 | 5 mg in 1 BOTTLE (24075-0413-9)Marketed from Oct 8, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Conjupri
- Generic name (nonproprietary)
- levamlodipine
- Active ingredients
- Levamlodipine maleate — 5 mg/5mg
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 212895
- Marketing start
- Listing expires
- Identifiers
- Product ID 24075-0413_22836378-d73e-4b0b-88bb-b82dd3420aabSPL ID 22836378-d73e-4b0b-88bb-b82dd3420aabSPL set ID c3cca66e-348a-43e8-8f96-e995104dae3dRxCUI 2377367, 2377369, 2377371, 2377373UNII 12WW9T2ITAUPC 0324075041158, 0324075041257
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N424075041303followed by a unit qualifier and the quantityPackage 24075-0413-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension CONJUPRI ® is indicated for the treatment of hypertension in adults and patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharm…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 212895
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Conjuprilevamlodipine | Levamlodipine maleate 2.5 mg/2.5mg | TabletOral | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411 |